Freeline Therapeutics

108 articles about Freeline Therapeutics

• Acquisition of Freeline by Syncona Becomes Effective

  2/20/2024

  Freeline Therapeutics Holdings plc and Syncona Ltd announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement, the Scheme has been sanctioned by the Court and the court order has been delivered to the Registrar of Companies.

• Freeline Shareholders Approve Acquisition by Syncona

  2/12/2024

  Freeline Therapeutics Holdings plc and Syncona Ltd announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited, a wholly owned subsidiary of Syncona Portfolio Limited, to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share in cash.

• Syncona to Acquire Freeline Therapeutics

  11/22/2023

  Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has entered into a definitive agreement with a newly established portfolio company of Syncona Ltd.

• Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

  10/25/2023

  Freeline Therapeutics Holdings plc announced that new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus gene therapy candidate for Gaucher disease, show a substantial reduction of glucosylsphingosine levels in the blood of the first patient treated with FLT201.

• Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

  10/4/2023

  Freeline Therapeutics Holdings plc reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus gene therapy candidate, in Gaucher disease.

• Freeline Reports Second Quarter 2023 Financial Results and Business Highlights

  8/15/2023

  Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the second quarter of 2023 and provided a business update.

• Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call

  8/8/2023

  Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.

• Freeline to Participate in Upcoming Investor Conferences - July 31, 2023

  7/31/2023

  Freeline Therapeutics Holdings plc announced that the company will be participating in two upcoming investor conferences in August.

• Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease

  7/25/2023

  Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated virus (AAV) gene therapy candidate in Gaucher disease Type 1, on Tuesday, August 1, 2023 at 8:30 a.m. ET.

• Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease

  6/26/2023

  Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the Phase 1/2 GALILEO-1 clinical trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease type 1.

• Freeline to Present at 2023 Jefferies Healthcare Conference

  6/2/2023

  Freeline Therapeutics Holdings plc announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies Healthcare Conference being held in New York on June 7-9, 2023.

• Freeline Completes ADS Ratio Change

  5/12/2023

  Freeline Therapeutics Holdings plc announced that the company’s previously disclosed change to its American Depositary Share to ordinary share ratio has been made effective prior to the open of business on May 12, 2023.

• Freeline Announces Proposed ADS Ratio Change

  4/21/2023

  Freeline Therapeutics Holdings plc announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value £0.00001 per share, from the current ADS Ratio of one ADS to one ordinary share to a new ADS Ratio of one ADS to fifteen ordinary shares.

• Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference

  4/12/2023

  Freeline Therapeutics Holdings plc announced that its Chief Executive Officer Michael Parini will present at the 22nd Annual Needham Virtual Healthcare Conference being held on April 17-20, 2023.

• Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update

  4/4/2023

  Freeline Therapeutics Holdings plc reported financial results for the full year ended December 31, 2022 and provided a corporate update.

• Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

  2/10/2023

  Freeline Therapeutics Holdings plc announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd., for $25 million, subject to purchase price adjustments.

• Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

  1/19/2023

  Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy.

• Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 05, 2023

  1/5/2023

  Freeline Therapeutics Holdings plc announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares.

• Freeline Receives Approval to Transfer to Nasdaq Capital Market - November 29, 2022

  11/29/2022

  Freeline Therapeutics Holdings plc announced that it received approval from the Nasdaq Stock Market LLC to transfer the listing of its American Depositary Shares representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.

• Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

  11/15/2022

  Freeline Therapeutics Holdings plc reported financial results for the third quarter of 2022 and announced its decisions to sell its CMC-focused subsidiary in Germany to Ascend Gene and Cell Therapies Ltd., streamline its organization to increase efficiency and strengthen its financial position, and prioritize the development of FLT201 in Gaucher disease and FLT190 in Fabry disease.